Provenge Approval Would Include Surveillance For Cerebrovascular Events
Executive Summary
A pharmacovigilence study involving roughly 3,000 patients would be conducted by Dendreon to monitor safety events associated with Provenge, if FDA approves the therapeutic cancer vaccine